Archive for the ‘Europe’ Category

Carlsbad, CA and Washington D.C., — October 14, 2008: Only a month remains
before BIO-Europe 2008, the world’s largest stand-alone partnering
conference, takes place in Mannheim/Heidelberg, Germany, November 17-19. In
response to the continuous growth and popularity of this well established
biotechnology partnering event, EBD Group is announcing additional
conference program highlights to offer even greater insight into a variety
of important industry topics.

If you wish to learn more about any of the sessions below, please visit the
BIO-Europe 2008 Program

Maximizing Your Deal – The Business Case for Translational Medicine in
Oncology:

Led by John Freshley, Compendia Bioscience, and featuring Dr. Ganesh Iyer,
MDS Pharma; Aron Knickerbocker, Genentech; and Dr. Linda Pullan, Pullan
Consulting; this session will explore the current and future state of
translational medicine in oncology and dealmaking.

Biotech-CMO Partnerships – Ways to Create Value:

Klaus Binder, Binder Associates and Marcel Lubben, DSM Biologics; will
confront the challenges in finding the right technologies and partners to
develop and manufacture biopharmaceuticals. In addition, the panel will shed
light on how biotech/pharma companies can identify partners and technologies
to optimize resources and accelerate timelines.

Critical Issues to Consider when Entering the U.S. Market and Partnering
with U.S. Companies:

Moderator Ray Briscuso, AdvaMed 2009 and panelists Dr. Steve Bryant, Genmab;
Joe Dillon, The Mattson Jack Group; Christopher Yochim, AstraZeneca; and
Jorn Mueller, NovoNordisk. This workshop will examine how to get timely U.S.
Food and Drug Administration approval, position products for the best
reimbursement and negotiate with governments, among other critical issues.

Dealmaking in China:

This session explores the rapidly growing life science and healthcare
industry in China. Led by Dr. Ruediger Herrmann, Mayer Brown; this workshop
will feature China experts Simon Bury, ChemPartner; Dr. Darren Ji,
PharmaLegacy Laboratories; Dr. Sofie Qiao, LEAD Therapeutics; and Dr. Jimmy
Wei, Hutchinson MediPharma; in a discussion on what Western companies
entering the Chinese market need to take into account, specifically in
relation to IP issues, business development, potential collaborations and
market conditions.

Dealmaking with Japanese Companies:

Japan is in a critical situation with sales figures of several major
products about to drop dramatically. Such circumstances have made it crucial
for Japanese pharmaceutical companies to seek licensing and M&A
opportunities outside of Japan. Dr. Richard Hammel, International Business
Consultants, will lead an expert panel on what to expect when partnering
with Japanese companies.

U.S. Patent Law in Flux – Can Dealmakers Adjust?:

Patents are key assets of biotech start-ups seeking partnering deals and
their sustainable strength determines the value of a deal for both sides.
Moderated by Sven Riethmueller, Foley & Lardner; and featuring Dr. Rouget
Henschel, Foley & Lardner; and Stephen S. Yoder, MorphoSys; this panel will
focus on potential strategies for navigating converging IP issues in the
context of dealmaking in the global life science industry.

Re-invention of the Drug Industry – Case Studies and the Implications for
Future Dealmaking:

Moderator Julie Teigland, Ernst & Young; is joined by Dr. Karsten Henco,
Neurimmune; Dr. Edwin Moses, Ablynx; Dr. Holger Reithinger, Global Life
Science Ventures; and Dr. Klaus Wilgenbus, Boehringer Ingelheim; to examine
which deals and business models help successful biopharmaceutical companies
evolve into successful future dealmakers.

The Early Stage Company – Preparing for Success:

This session will provide insight into developing a sound business and legal
strategy to make a company attractive for future deals and investment.
Moderator Diane Romza-Kutz, Neal, Gerber & Eisenberg; and panelists Steve
Damon, Altea Therapeutics; Tim Edwards, Cellzome; and Dr. Peter Johann, NGN
Capital; will discuss how companies can design, implement and fund growth
strategies.

Early Stage Dealmaking – How to Build Value Instead of Giving it Away:

In the current financial environment it is even more tempting for biotechs
to strike deals early. Dr. Neill Moray Mackenzie, Roji; Guido Lanza,
Numerate; and Dr. Sarah Holland, Roche; will participate in an expert panel
confronting the pros and cons of the different strategic imperatives for
biotech and pharma in striking a deal.

What Buyers Want – Understanding What Big Pharma Expects to See in
Out-Licensing Documents:

Moderated by Ben Bonifant, Campbell Alliance; and featuring Lubor Gaal,
Bristol-Myers Squibb; Gwen Melincoff, Shire Pharmaceuticals; and Dr. Corinne
Savill, Novartis Pharma; this session provides a comprehensive cost/benefit
analysis of how to gather and deliver information that is essential to a
compelling out-licensing document.

Biomarkers – Leading the Way for Personalized Medicine and Drug Development:

The commercialization of biomarkers still faces challenges on several fronts
including regulatory framework, IP ownership, value sharing and business
models. Moderated by Dr. Albine Martin, Compugen; this session will examine
the growth and integration of biomarkers into the discovery and delivery of
new medicines.

Transformative Trends in Oncology:

The complex pathogenesis of cancer and the limitations associated with and
posed by current cancer management have led to the development of various
novel approaches such as targeted immunotherapy, angiogenesis inhibitors,
signal transduction inhibitors, novel cytotoxics, and gene therapy.
Moderated by Gardiner Smith, SHI Link; and joined by Dr. William Levine,
Izun Pharmaceuticals; and Dr. Melinda Shockley, Medarex; this session will
discuss advances in supportive care therapy and novel therapeutic approaches
to cancer, and will aim to generate a stronger support for innovative
therapeutic approaches to cancer.

Notes to Editors:

Entry to BIO-Europe 2008 is free to the media, including full access to the
partnering system, sessions, press conferences, workshops, and pre-arranged
partnering meetings. Visit the BIO-Europe conference Web site at
http://www.ebdgroup.com/bioeurope for detailed information on this year’s
conference and online registration. When you register online, please
indicate in the comment field that you are requesting a complimentary press
registration. Please fax a copy of your press pass to complete your
complimentary media registration to fax number +49 89 23 88 756-55.

About BIO-Europe

BIO-Europe is the preeminent stand-alone partnering event for the
biotechnology industry. Delegates from all parts of the biotechnology
value-chain come to BIO-Europe to efficiently identify, engage and enter
into the strategic relationships that drive their business successfully
forward. The annual BIO-Europe partnering event draws over 2,200 industry
attendees from almost 50 countries, representing more than 1,250 companies,
for three days of high-level networking. BIO-Europe is organized by EBD
Group with the support of the Biotechnology Industry Organization and
European Biopharmaceutical Enterprises.

About EBD Group

EBD Group is the leading partnering firm for the global life science
industry. Since 1993, biotech, pharma and medical device companies have
leveraged EBD Group’s partnering conferences, technology and services to
identify business opportunities and develop strategic relationships
essential to their success.

EBD Group’s conferences are run with the support of leading corporations and
international trade associations and include:

.     BIO-Europe and BIO-Europe Spring(R), the world’s largest stand-alone
life science partnering conferences, supported by the Biotechnology Industry
Organization (BIO)

.     BioPharm America(TM), EBD Group’s North American partnering event

.     EuroMedtech(TM), EBD Group’s new partnering event for the innovative
medical technology industry

.     BioEquity Europe, the investor conference co-organized with BioCentury
Publications and BIO

EBD Group’s sophisticated Web-based partnering service, partneringONE(TM),
is used as the partnering engine at numerous third-party events around the
world. Outside of the conference format, EBD Group’s consultants provide
hands-on assistance for firms seeking to in- or out-license products and
technologies.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com

About BIO

BIO represents more than 1,200 biotechnology companies, academic
institutions, state biotechnology centers and related organizations across
the United States and in more than 30 other nations. BIO members are
involved in the research and development of innovative healthcare,
agricultural, industrial and environmental biotechnology products. BIO also
produces the BIO International Convention, the world’s largest gathering of
the biotechnology industry, along with industry-leading investor and
partnering meetings held around the world.

Conference Returns to Location of its Inaugural Event on March 16-19, 2009

Carlsbad, USA and Madrid, Spain, April 9, 2008 – Coming on the heels of BIO-Europe Spring 2008 in Madrid where delegates engaged in an incredible 5800 one-to-one meetings, EBD Group today announced that the third annual BIO-Europe Spring 2009 partnering conference will be returning to Milan, Italy, the site of its highly successful inaugural event. BIO-Europe Spring 2009 will open its doors at the Milano Convention Center (MIC), March 16-18, 2009

BIO-Europe Spring in only its second year has become the second largest dedicated partnering event in the biotechnology industry.  Biotechnology companies from around the world participate in BIO-Europe Spring to identify and meet with companies across the life science value-chain, from large biotech and pharma companies to financiers and innovative start-ups.

Commenting on the return of BIO-Europe Spring to Milan, Professor Rossi Bernardi, Commissioner for Research, Innovation and Human Capital, The City of Milan, stated: “The City of Milan, which has been recently chosen by BIE as host of the world exhibition EXPO 2015, is looking forward to host the 2009 edition of BIO-Europe Spring.”

“We are excited that BIO-Europe Spring is returning to Italy. The conference is a unique opportunity for leaders of the global biotech and pharma community to meet in a setting conducive to doing business,” said  Edoardo Richter, Director International Division, Angelini Group. “As an Italian pharmaceutical company, the BIO-Europe Spring event helps to shine more light on the rapid progress of our industry, the exceptional quality of our scientific programs and the great potential for partnering with Italian firms.

“We look forward to bringing BIO-Europe Spring back to the city of Milan and another highly productive and dynamic conference,” said Carola Schropp, President of EBD Group. “Partnering has become the life blood of our industry. This is a phenomenon readily apparent to anyone attending the currently in-session BIO-Europe Spring 2008 in Madrid, where 1400 delegates from 838 companies are engaging in over 5800 partnering meetings.

About EBD Group:

EBD Group is the leading partnering firm for the global biotechnology industry. Since 1993, firms in the life sciences have leveraged EBD Group’s partnering conferences, technology and services to identify opportunities and to develop strategic relationships that drive their business.

EBD Group’s conferences (run in collaboration with leading industry partners and international trade associations) include BIO-Europe, the world’s largest stand-alone life science partnering conference (organized with the support of the Biotechnology Industry Organization, BIO); BIO-Europe Spring(R); BioPharm America(TM) (EBD’s new North American partnering event); and BioEquity Europe (co-organized with BioCentury Publications and BIO).

EBD’s sophisticated web-based partnering service, partneringONE(TM), is also used at numerous third-party events around the world. Outside of the conference format, EBD’s consultants can provide hands-on assistance for firms seeking to in- or out-license products and technologies. EBD Group has offices in the USA and Europe.

For more information visit www.ebdgroup.com

Select Biosciences is proud to announce their first conference devoted to Advances in Synthetic Chemistry. The meeting will focus primarily on Flow Chemistry and Microwave-Assisted Organic Synthesis.

Alongside an exhibition of selected scientific posters and service providers, Select Biosciences is organizing a two day conference gathering some of the most influential researchers in the field including :

• Oliver Kappe, Associate Professor of Chemistry, University of Graz
• Ferenc Darvas, President, Thales Nanotechnology
• Fredrik Almqvist, Research Director, Biological Chemistry, UmeÃ¥ University
• Mark Bagley, Senior Lecturer, University of Cardiff
• Ian Baxendale, Research Fellow, University of Cambridge
• Carsten Bolm, Professor, RWTH Aachen
• Maurizio Botta, Professor, University of Siena
• Marcus Koppitz, Senior Scientist, Bayer Schering Pharma
• Fernando Langa, Professor, University Castilla-La Mancha
• Vincenzo Santagada, Professor of Medicinal Chemistry, University of Naples
• Peter Seeberger, Professor, ETH Zurich
• Brian Warrington, Director, BB Consultants Ltd
• Catherine Smith, University of Cambridge
• Mark Bagley, Senior Lecturer, University of Cardiff
• Sven Schroeder, Professor, University of Manchester
• And many more…

To guarantee a high attendance Select Biosciences will maintain their traditional low registration fees and group booking discounts. Furthermore, to encourage educational development, special priced passes are available to students as are one-day passes for the busy researcher who can’t spare time for the full two days.

About Select Conferences http://www.selectconferences.com

The conferences division of Select Biosciences Ltd. is focused on organizing specialist biomedical meetings each year. Experts from both academia and commerce are invited to present timely information from current research through to commercial implementation of new technologies. These events also provide a unique networking facility and the opportunity to reach a highly targeted scientific audience.

The essence of synthetic biology is that techniques used to build non-biological systems in the engineering and computational sciences could potentially be used to build novel synthetic biosystems. The sessions will develop the following topics:

• Regulatory, IP, Ethical and Business Issues
• Protein, Metabolic & Therapeutic Engineering
• Design & Fabrication of Parts: Devices and Systems
• Cell & Tissue Engineering

Advances in Synthetic Biology, will be held on 6-7 March, at the Wellcome Trust Genome Campus, home to the Sanger and European Bioinformatics Institutes in Cambridge suburb. Both historically and today, the beautiful city of Cambridge is positioned at the forefront of scientific advancement and appears to be an ideal venue for such a meeting.

Alongside an exhibition of selected scientific posters and service providers, Select Biosciences is organising a two day event gathering world players in the field.

• Peter Ghazal, Director of Division of Pathway Medicine, Edinburgh University, UK
• Andreas Herrmann, Professor for Polymer Chemistry and Bioengineering, University of Groningen, NL
• Alfonso Jaramillo, Assistant Professor, Ecole Polytechnique, FR
• Juan Poyatos, Associate Professor, Spanish National Research Council, ES
• Laurie Zoloth, Professor, Northwestern University, US
• And many more…

To guarantee a high attendance at Europe’s largest conference dedicated to synthetic biology, Select Biosciences will maintain their traditional low registration fees and group booking discounts. Students will also benefit from special rates.

All conference passes include entrance to the sessions, the exhibition, as well as conference documentation, lunch and refreshments

To further increase the value of their trip, delegates can opt to attend a free guided tour of the Sanger Institute, the largest sequencing facilities in Europe! Early booking is necessary as numbers are strictly limited.

SyntheticBiologyAdvances.com

About Select Conferences http://www.selectconferences.com

The conferences division of Select Biosciences Ltd. is focused on organising specialist biomedical meetings each year. Experts from both academia and commerce are invited to present timely information from current research through to commercial implementation of new technologies. These events also provide a unique networking facility and the opportunity to reach a highly targeted scientific audience.